Publication: Cancer Discovery. 4(3): 362-375.
Published Date: March 2014
Describes novel method of determining mitochondrial response of acute myeloid leukemia (AML) cells to treatment with a BCL-2 antagonist (ABT-199).
AML is associated with high mortality rates because of chemotherapy resistance. Therefore, the authors suggest a profiling strategy to determine whether patients will be responsive to anti-cancer treatments with ABT-199, which stimulates cell death by targeting mitochondrial apoptosis pathways, by examining the expression of BCL-2 proteins in patient cell lines. The study found that ABT-199 selectively kills cells that are BCL-2-dependent at the mitochondrial level, and demonstrates that pre-screening patient samples may increase efficacy of AML treatments.